RT Journal Article SR Electronic T1 Drug repositioning with gender perspective focused on Adverse Drug Reactions JF bioRxiv FD Cold Spring Harbor Laboratory SP 2022.07.22.501091 DO 10.1101/2022.07.22.501091 A1 Otero Carrasco, Belén A1 Pérez Pérez, Aurora A1 Ruiz, Ernestina Menasalvas A1 Caraça-Valente Hernández, Juan Pedro A1 Prieto Santamaría, Lucía A1 Rodríguez-González, Alejandro YR 2022 UL http://biorxiv.org/content/early/2022/07/23/2022.07.22.501091.abstract AB Drug repositioning is a novel, useful, and crucial technique to find new uses for existing drugs. In this field of study, when the clinical trials necessary to obtain successful drug repositioning have been carried out, the female gender has not been given much consideration. Thus far, the participation of women in clinical trials has been very limited. There were several argued reasons to exclude them from trials, like the likelihood of pregnancy or sudden hormonal changes. This has meant that for a long time the adverse effects of a drug on women were unknown. Scientifically, it was known that due to the biological processes of pharmacokinetics and pharmacodynamics, the response to drugs was not the same in both genders, but despite this evidence, there is still no difference in the dosage or form of using a drug between men and women. In this study, we made a preliminary analysis where the main goal is to investigate gender differences within the drug repositioning field through the adverse effects produced by such treatments. A special section on specific cases of drug repositioning in rare diseases will also be considered to carry out the same verification previously mentioned in the text.Competing Interest StatementThe authors have declared no competing interest.